secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001140361-25-005427
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility
--------------------------------------------------------------------------------

- Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.
- New ATM with H.C. Wainwright allows sale of up to $75M of common stock at market prices.
- Wainwright receives 3.0% commission on gross proceeds from each sale.
- Shares sold on Nasdaq through at-the-market offerings; company may suspend at any time.
- Registration statement on Form S-3 effective May 10, 2023, covering the new facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000114036125005427/0001140361-25-005427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000114036125005427/ef20043949_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer